![]() |
Name |
3,4-Dihydropiplartine
|
Molecular Formula | C17H21NO5 | |
IUPAC Name* |
1-[3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]piperidin-2-one
|
|
SMILES |
COc1cc(C=CC(=O)N2CCCCC2=O)cc(OC)c1OC
|
|
InChI |
InChI=1S/C17H21NO5/c1-21-13-10-12(11-14(22-2)17(13)23-3)7-8-16(20)18-9-5-4-6-15(18)19/h7-8,10-11H,4-6,9H2,1-3H3/b8-7+
|
|
InChIKey |
HPXUNEGPCPQBQY-BQYQJAHWSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 319.36 | ALogp: | 2.3 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.1 | Aromatic Rings: | 2 |
Heavy Atoms: | 23 | QED Weighted: | 0.781 |
Caco-2 Permeability: | -4.688 | MDCK Permeability: | 0.00002160 |
Pgp-inhibitor: | 0.954 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.263 |
30% Bioavailability (F30%): | 0.307 |
Blood-Brain-Barrier Penetration (BBB): | 0.98 | Plasma Protein Binding (PPB): | 90.11% |
Volume Distribution (VD): | 0.419 | Fu: | 10.49% |
CYP1A2-inhibitor: | 0.862 | CYP1A2-substrate: | 0.942 |
CYP2C19-inhibitor: | 0.421 | CYP2C19-substrate: | 0.887 |
CYP2C9-inhibitor: | 0.336 | CYP2C9-substrate: | 0.764 |
CYP2D6-inhibitor: | 0.124 | CYP2D6-substrate: | 0.617 |
CYP3A4-inhibitor: | 0.286 | CYP3A4-substrate: | 0.607 |
Clearance (CL): | 8.68 | Half-life (T1/2): | 0.814 |
hERG Blockers: | 0.085 | Human Hepatotoxicity (H-HT): | 0.423 |
Drug-inuced Liver Injury (DILI): | 0.089 | AMES Toxicity: | 0.018 |
Rat Oral Acute Toxicity: | 0.058 | Maximum Recommended Daily Dose: | 0.06 |
Skin Sensitization: | 0.947 | Carcinogencity: | 0.275 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.051 |
Respiratory Toxicity: | 0.098 |